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The incidence of melanoma is increasing in many countries, 
particularly in populations with white skin.[1-3] Australia has the 
highest melanoma incidence in the world, but public health campaigns 
have helped to stabilise the incidence in younger individuals, coupled 
with stabilising/reducing mortality rates in all groups apart from 
older males.[4] Melanoma is an aggressive cancer when detected late. 
If it is diagnosed early, 5-year survival is >90%; if it is diagnosed late, 
5-year survival is ~20%.[3]
In South Africa (SA), incidence data on melanoma are limited 
or out of date. Studies have focused on a single population 
group[5,6] or a single province.[5-7] Skin cancer incidence data were 
last reported for 2000 - 2004 (inclusive), showing differences in 
incidence rates and body sites by population group and gender. [8] 
Melanoma is more common in fair than dark individuals, but 
does occur in black Africans. Since the black African group is 
the largest in SA, melanoma in this group has significant public 
health implications.[9] While melanoma in white individuals is 
most commonly of the superficial spreading histological subtype 
and typically affects the trunk in males and the legs in females,[9] 
melanoma in deeply pigmented people is more likely to be the acral 
lentiginous histological subtype affecting the palms and soles.[9-12] 
Several studies have reported worse disease outcomes for melanoma 
patients with darker skin types[10,12,13] and melanoma of hands and 
feet.[1,14]
Objectives
Variation in reported SA incidence rates of melanoma[5,7-9] makes it 
difficult to form robust conclusions. Incidence rates ranging from 
11.8 per 100 000 in white females in Northern Cape Province[7] to 69 
per 100 000 for the white population in Western Cape Province have 
been reported.[9] For black Africans, the incidence rate is about 1 per 
100 000.[9] The objective of this study was to analyse and describe the 
most recent age-standardised melanoma incidence rates from the 
National Cancer Registry (NCR) by population group, gender and 
province in SA. Additional data were sought to inform a detailed 
analysis of black African individuals presenting with melanoma, 
specifically melanoma of the limbs (defined as shoulder to and 
including hand, and hip to and including foot), since there is evidence 
that this group of melanoma patients tends to have a worse prognosis 
than other melanoma patients.[13,14] This is the first nationwide study 
in which detailed information, i.e. Breslow depth (BD) and stage at 
diagnosis, on melanoma in black South Africans has been analysed, 
and it will be useful to inform skin cancer awareness and screening 
programmes.[9]
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Background. Melanoma is an aggressive skin cancer with poor survival when diagnosed late. There are important differences in clinical and 
histological features of melanoma and disease outcomes in people with darker skin types.
Methods. A retrospective review of data captured by the National Cancer Registry (NCR) of South Africa (SA) was performed for 2005 - 
2013. Data on patient numbers, demography, location and biological features were analysed for all records. Closer analysis of melanoma of 
the limbs reported in black Africans was done after manually collecting this information from original reports.
Results. With 11 784 invasive melanomas reported to the NCR, the overall incidence of melanoma for SA was 2.7 per 100 000. Males (51%), 
individuals aged ≥60 years (48%) and the anatomical sites of lower limb (36%) and trunk (27%) were most commonly affected. Melanoma 
incidences in the white and black populations were 23.2 and 0.5 per 100 000, respectively. Most cases were diagnosed at private pathology 
laboratories (73%). Superficial spreading melanoma (47%) and nodular melanoma (20%) predominated. Among 878 black Africans 
diagnosed in the public sector with melanoma of the limbs, females (68%) and individuals aged ≥60 years (61%) were most commonly 
affected. Lower-limb lesions (91%) and acral lentiginous melanoma (65%) predominated, with 74% of cases affecting the foot and 62% of 
cases presenting with a Breslow depth >4 mm.
Conclusions. This study provides up-to-date NCR incidence and demographic data on melanoma and highlights the neglected research 
gaps in relation to melanoma in black Africans to provide evidence needed to address health disparities in overlooked population groups.
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247       April 2019, Vol. 109, No. 4
RESEARCH
Methods
Study design and data
This was a retrospective observational study of the NCR database. 
The NCR is a pathology-based registry that records all cancer cases 
diagnosed by histology or cytology in public and private healthcare 
laboratories throughout SA.[15] The study examined melanoma cases 
reported to the NCR from 2005 to 2013 (inclusive), 2013 being 
the most recent year for which data were available at the time of 
writing, and included data from mandatory cancer reporting that was 
legislated in 2011 (between 2004 and 2011 some private laboratories 
discontinued reporting to NCR).[15] Cancers were coded according to 
the International Classification of Diseases for Oncology, 3rd edition 
(ICD-O3),[16] providing morphology and topography codes.
Data by population group, age and anatomical site
In a significant number of cases, the population group of patients 
reported to the NCR was not stated. These cases were classified 
by comparing their surnames with a large reference database of 
surnames, updated on a continuous basis, of known population 
groups. A hot-deck imputation method was used to assign population 
group to individuals.[8]
Melanoma cases were divided into age bands defined as <40, 
40 - 59 and ≥60 years of age, since melanoma is typically reported 
to occur in middle age, except for specific subtypes such as lentigo 
maligna melanoma that usually occur in older individuals. Only 
2% of melanomas occur in patients aged <2 years.[3] Melanomas 
in individuals <40 years of age may have unique phenotypic and 
genetic features.[17] When extracting data on melanoma location, skin 
included all tumours coded according to the ICD-O3 as C44 (skin 
of various sites), C51 (skin of female genitalia), C60 (skin of male 
genitalia, including glans) and C63 (skin of scrotum).
Incidence rates for all and by population group
Annual melanoma incidence rates were estimated for 2005 - 2013 
using at-risk mid-year population estimates from updated 2005 - 
2013 mid-year population estimates in the 2017 mid-year population 
data (provided by Prof. Rob Dorrington of the Centre for Actuarial 
Research at the University of Cape Town). Annual incidence rates 
were standardised against a World Health Organization world 
population using age. For those patients who could not be assigned 
a population group based on the aforementioned hot-deck approach, 
missing data were distributed proportionally to the observed 
distribution for incidence estimates for year and population group. 
Data were prepared in Excel 2013 (Microsoft, USA) and analysed 
using Stata 14 (StataCorp, USA).
Additional data analysed specifically for black Africans
The NCR manually extracted additional data on each case for black 
African patients only, diagnosed with melanoma of the limbs from 
2005 to 2013 from NCR public National Health Laboratory Service 
(NHLS) data. Data on NHLS patients were more readily available than 
data on private patients. Patients with ICD-O3 topography codes C44.6 
(skin of upper limb, shoulder) and C44.7 (skin of lower limb, hip) were 
extracted. An attempt was made to ascertain exact anatomical site, BD 
and stage of disease by closer examination of reports.
Anatomical site, Breslow depth and staging
Owing to large detail variations from one pathology report to another, 
‘hand’ was taken to include nonspecific ‘hand’ or anything indicating 
involvement of finger or palmar skin. Lesions clearly involving the 
dorsum of the hand were included in the ‘other’ group. A similar 
approach was made for foot and plantar skin. The ‘other’ group 
included lesions involving the dorsum of the hand and foot as well as 
more distant sites, i.e. elbow/knee. Only when clearly documented to 
involve the nail was the lesion included in the ‘nail’ group.
BD measurements were grouped according to the accepted 
pathological staging of tumour (T) component with T1 ≤1.0 mm, 
T2 = 1.01 - 2.0 mm, T3 = 2.01 - 4.0 mm and T4 >4.0 mm.[3] Clark 
depth according to the American Joint Committee on Cancer staging 
system was captured.[3]
Disease stage was recorded according to pathologist diagnosis 
when clinical or pathological staging was available. Staging was 
according to the TNM Classification of Malignant Tumors,[3] and 
where only limited data were available (e.g. ‘metastasised’), this was 
also recorded.
Ethics approval
Ethics approval was obtained from the Stellenbosch University 
Health Research Ethics Committee (ref. no. N15/12/129A).
Results
Sample description and annual melanoma incidence 
rates in all population groups
A total of 11 784 invasive (i.e. excluding in situ) melanomas were 
reported to the NCR for 2005 - 2013 (inclusive). Of these, 5 727 
(49%) occurred in females and 6 049 (51%) in males (in 8 cases sex 
was unknown) (male/female gender ratio 1:0.9). A total of 1 801 
melanomas (15%) were recorded in the age group <40 years, 4 178 
(35%) in the age group 40 - 59 years and 5 662 (48%) in the age group 
≥60 years. Melanoma frequencies were highest in the white group 
(n=8 104), followed by 1 991 melanomas in black Africans, 1 070 in 
coloured individuals (of mixed ancestry) and 106 in Indians/Asians. In 
513 cases population group was unknown. The incidence of melanoma 
for SA was 2.6 per 100 000 (Table 1). A striking dip in the number 
of cases reported in 2009 and 2010 was probably related to under-
reporting from private laboratories prior to 2011. When post-2011 
data were used, the national melanoma incidence was 2.7 per 100 000.
Western Cape and Gauteng provinces had the highest melanoma 
incidence rates, followed by the Northern Cape (Table 2). Nearly 75% 
of all melanomas in all population groups were diagnosed in private 
laboratories (Table 1), while 75% of melanomas in black Africans 
were diagnosed in the public sector.
Ninety-six percent (n=11 266) of melanomas primarily involved 
the skin and 518 (4%) involved extracutaneous sites (including 
ocular, mucosal, central nervous system and ‘unknown primary site’). 
Of cutaneous melanomas, 4 247 (38%) were reported as ‘Skin, not 
otherwise specified (NOS)’. Fig. 1 shows the percentage involvement 
of body areas by cutaneous melanoma for all population groups. For 
extracutaneous melanoma (Table 3), ‘Other sites’ refers to diverse 
areas (from lung to colon), probably owing to metastatic disease 
and possibly instances of misreporting. Ocular melanoma could 
not be classified into conjunctival, uveal tract and other ocular sites 
owing to existing divisions of the ICD-O3 coding system (Table 4). 
Morphological descriptions (Table 5) show a low frequency of 
mucosal lentiginous melanomas (0.03%) (morphology code) v. a 
higher frequency reported at mucosal sites (0.5%) (topography code), 
probably owing to variations in reporting detail and the fact that not 
all mucosal melanomas have this specific morphology.
Where specific histological subtype was recorded, superficial 
spreading melanoma predominated with 47% cases, followed 
by nodular (20%), acral lentiginous (11%) and lentigo maligna 
melanoma (9%).
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Melanoma on the limbs in black Africans in the  
public sector
Melanoma in black Africans (n=1 991) occurred mostly in the skin 
(92%) and to a lesser extent in mucosa, ocular and other/extra-
cutaneous/unknown sites. Fig. 2 shows the percentage involvement 
of body areas by cutaneous melanoma in all black African patients. 
Of all the melanomas occurring on the limbs in all population 
groups, 27% originated in black Africans.
A total of 878 black Africans were diagnosed with melanoma of 
the limbs (68% were female and 32% were male; in 3 cases sex was 
unknown). The majority were aged ≥60 years (n=515, 61%) followed 
by ages 40 - 59 years (n=268, 32%) and <40 years (n=62, 7%). The 
Table 1. Annual incidence rates for melanoma by sex, population group and age group, and counts by year of patients with 
melanoma in the public (NHLS) and private sector, and specifically for black Africans with limb melanoma





Annual incidence rates,  
/100 000/year
All 2.9 2.8 2.6 2.6 2.0 2.0 2.6 2.8 2.9 2.6 2.7
Gender
Male 3.2 2.9 2.7 2.8 2.0 2.2 2.8 2.8 3.1 2.7 2.9
Female 2.7 2.6 2.4 2.4 2.0 1.9 2.4 2.7 2.6 2.4 2.6
Population group
Black African 0.6 0.6 0.6 0.6 0.6 0.4 0.5 0.6 0.5 0.5 0.5
Coloured 2.7 3.0 2.6 2.7 2.2 2.2 2.9 3.0 2.9 2.7 2.9
Indian/Asian 0.9 0.8 1.2 1.2 0.4 0.7 1.0 0.9 1.3 0.9 1.1
White 22.1 20.8 19.2 19.6 14.5 16.2 21.0 23.0 25.5 20.2 23.2
Age group (years)
≤39 0.7 0.6 0.6 0.6 0.3 0.4 0.5 0.4 0.4 0.5 0.4
40 - 59 6.0 5.8 5.3 4.9 4.2 4.3 4.8 5.4 5.4 5.1 5.2
≥60 18.0 17.7 15.9 17.2 13.4 13.0 18.2 18.6 20.1 16.9 19.0
Counts by year, n
Public v. private
NHLS counts 379 313 357 367 381 322 335 396 323 3173 1 054
Private counts 1 032 1 036 915 928 645 735 1 026 1 075 1 219 8 611 3 320
Black Africans diagnosed 
with melanoma of the limb
112 106 115 53 53 75 126 130 108 878 -
NHLS = National Health Laboratory Service.
Table 2. Annual incidence rates for melanoma by South African province, 2011 - 2013*
 Annual incidence rates, /100 000 Black Africans in NHLS with 
melanoma (2005 - 2013), n (%)Province Capital city latitude 2011† 2012 2013 All 2011 - 2013
Eastern Cape Bhisho
32° 50΄ S
1.9 2.1 1.8 1.9 158 (18)
Free State Bloemfontein
29° 5΄ S
2.9 3.4 4.0 3.4 90 (10)
Gauteng Johannesburg
26° 12΄ S
4.3 4.3 4.6 4.4 233 (26)
KwaZulu-Natal Pietermaritzburg
29° 36΄ S
0.7 0.7 0.7 0.7 97 (11)
Limpopo Polokwane
23° 53΄ S
0.8 0.9 0.4 0.7 115 (13)
Mpumalanga Nelspruit
25° 28΄ S
1.2 0.9 1.1 1.1 69 (7)
Northern Cape Kimberley
28° 43΄ S
3.9 5.4 5.7 5.0 15 (1)
North West Mahikeng
25° 51΄ S
0.3 0.6 0.6 0.5 56 (6)
Western Cape Cape Town
33° 55΄ S
6.8 7.5 8.0 7.5 45 (5)
NHLS = National Health Laboratory Service.
*Latitude of provincial capital city is provided. Also provided by province is the number and percentage of black African patients diagnosed in the NHLS with melanoma of the limb.
†Data prior to 2011 were not analysed for all population groups owing to inadequate reporting prior to the implementation of mandatory reporting.
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highest number of melanomas of the limbs 
in black Africans was diagnosed in Gauteng 
(n=233, 27%), followed by the Eastern Cape 
(n=158, 18.0%) and Limpopo (n=115, 13%) 
(Table 2). Other provinces had <100 cases 
each.
Of black Africans diagnosed with limb 
melanoma, fewer (n=81, 9%) were coded as 
having melanomas with topography codes of 
C44.6 (upper limb) than melanomas of the 
lower limb (n=797, 91%) (code C44.7).
Specific locations were highest for the foot 
(n=652, 74%) followed by other areas of the 
limb (n=84, 10%), the hand (n=47, 5%), the 
nail apparatus (n=15, 2%) and unknown 
sites (n=80, 9%). Relative frequencies of 
patho logical (morphological) subtypes of 
mela noma reported in black Africans with 
melanoma of limbs are set out in Table 6. 
After excluding the NOS code, 65% of mela-
nomas were acral lentiginous melanomas 
and 10% were nodular melanomas.
BD was recorded in 347 cases of melanoma 
of the limbs (39%) in black Africans. In the 
majority, BD was >4 mm (n=222, 64%), 
followed by 2.01 - 4 mm (n=75, 22%) and 
then 1.01 - 2 mm (n=30, 9%) and <1 mm 
(n=20, 6%). The largest BD recorded was 
95  mm. Distribution of BDs was fairly 
similar for upper- and lower-limb lesions. 
Each group tended to present late with large 
BDs, so for the upper limb 72% presented 
with BDs >4  mm, and for the lower limb 
62% presented with BDs >4 mm. Similarly, 
where Clark level was known, patients 
mainly presented with Clark levels IV and 
V (85% of those with known Clark level). 
Staging information was only available for 
86 patients. Of these, partial staging was 
stated in 7 patients, 26 were in stage I or II, 
and 53 were in stage III, IV, ‘advanced’ or 
‘metastasised’.
Discussion
The national melanoma incidence rate 
based on cases reported to the NCR was 
<3 per 100 000, with men having a slightly 
higher incidence than women. This figure 
is lower than the previous study (mean 
age-standardised annual incidence for the 
population as a whole of 5.3 per 100 000 
for men and 3.9 per 100 000 for women);[8] 
however, this change must be interpreted 
with care as it probably does not reflect a 
true reduction in incidence. Incomplete case 
reporting to the NCR is possibly responsible, 
and factors such as a small population 
reduction in the percentage of whites (who 
are more likely to experience melanoma than 
other groups) in the population as a whole 
Cutaneous, lip: n=16 (0.2%)
Cutaneous, eyelid: n=34 (0.5%)
External ear: n=184 (2%)
Other areas of face: n=515 (7%)
n=749 (11%)
Scalp and neck: n=422 (6%)
Upper limb and shoulder: n=1 355 (19%)
Trunk: 
n=1 901 (27%)
Lower limb and hip: n=2 549 (36%)
Cutaneous, genitalia: n=38 (0.5%)
•  Skin, NOS: n=4 247 (38% of total group of 
cutaneous melanomas) 
This group was excluded from this diagram, 
which shows relative frequencies of involvement 
among 7 019 cutaneous melanomas with 
known location
•  Overlapping lesions: n=5
Fig. 1. Distribution of melanoma incidence as a frequency count (and as a percentage of all body sites in 
parentheses) by anatomical site for all population groups. (NOS = not otherwise specified.)
Table 3. Relative frequencies of extracutaneous melanoma, 2005 - 2013
Frequency (N=11 784), n % % after exclusion of cutaneous melanomas (N=518)
Eye and ocular apparatus 127 1 24
Central nervous system 2 0.02 0.3
Mucosal sites 67 0.5 12
Other sites* 322 3 62
*‘Other sites’ refers to diverse organs ranging from the lung to the colon, probably representing metastatic disease. It also includes lesions designated as ‘Unknown primary site’.
Table 4. Relative frequencies of eye and ocular apparatus involvement, 2005 - 2013 (excludes eyelids)
Frequency (N=11 784), n Ocular lesions, %
Conjunctiva 24 19
Cornea, NOS; limbus of cornea 2 2
Retina 1 0.7
Choroid* 22 17
Ciliary body, crystalline lens, iris, sclera, uveal tract, intraocular, eyeball 14 11
Orbit, NOS; autonomic nervous system of orbit; connective tissue of orbit, extraocular 
muscle, peripheral nerves of orbit, retrobulbar tissue, soft tissue of the orbit
5 4
Eye, NOS 59 46
NOS = not otherwise specified.
*Components of the uveal tract are highlighted in bold (ciliary body may or may not be included).
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between 2005 (when white individuals 
comprised 9.3% of SA’s population) and 
2013 (8.7%) may have contributed.[18,19] 
Ongoing analysis of NCR numbers and 
external validation are needed to confirm 
these numbers.
The typical trend of increasing melanoma 
incidence in older patients was evident, with 
the highest incidence rates observed in the 
≥60-year-old group.[8,20] The elderly represent 
an important age group for screening, but 
clinicians should aim to diagnose mela-
noma in its in situ phase whenever possible, 
so ideally screening should start earlier. 
Annual melanoma screening is justified in 
individuals between 35 and 75 years of age 
if the individual has one or more risk factors 
for melanoma[21] and may be feasible in SA, 
but depends highly on affordability and 
healthcare access.
There is some evidence to suggest a slight 
increase in melanoma incidence in the white 
group compared with the previous study,[8] 
but this differs from other previous studies 
of melanoma incidence in white individuals 
in Cape Town, and again must be interpreted 
with caution.[5,6] Comparing study findings 
is difficult owing to different methodologies 
and populations of interest. The Western 
Cape data showed high incidences in whites 
(33.5 per 100 000 in females and 36.9 per 
100  000 in males for 2001 - 2003) in Cape 
Town.[6] The Northern Cape study found 
incidence rates for 2008 - 2012 of <20 per 
100 000 for Whites.[7] These regional studies 
used pathology data, which may have 
improved accuracy, but their conclusions 
cannot be generalised.
It is interesting to consider that the inci-
dence rate of melanoma for white South 
Africans is less than half that reported in 
Australia (72 per 100 000 in 2010 - 2014 for 
the entire population),[4] as there are likely to 
be similarities in lifestyle among white indivi-
duals living in the two countries. Differences 
may arise from different thresholds for 
classifying grey-area lesions (severely dysplastic 
naevus v. melanoma) as melanomas,[4] missed 
reporting to the NCR, an increased prevalence 
of risk factors in Australia, or a combination of 
these or other factors.
Each population has its own profile 
and prevalence of individual melanoma 
risk factors such as number of naevi per 
Table 5. Relative frequencies of pathological (morphological) subtypes of melanoma, 2005 - 2013
Morphological description
Frequency 
(N=11 784), n %
% after exclusion of NOS 
code (N=5 063)
Malignant melanoma, NOS (except juvenile melanoma) 6 721 57 -
Superficial spreading melanoma 2 366 20 47
Nodular melanoma 1 005 9 20
Acral lentiginous melanoma 555 5 11
Lentigo maligna melanoma 449 4 9
Epithelioid cell melanoma 199 2 4
Amelanotic melanoma 149 1 3
Spindle cell melanoma, NOS 137 1 3
Mixed epithelioid and spindle cell melanoma 85 0.7 2
Desmoplastic melanoma 47 0.4 0.9
Malignant melanoma in a giant pigmented naevus 18 0.1 0.3
Malignant melanoma in junctional naevus 17 0.1 0.3
Spindle cell melanoma, type B 14 0.1 0.2
Malignant melanoma, regressing 6 0.1 0.1
Malignant melanoma in precancerous melanosis 5 0.04 0.1
Blue naevus, malignant 5 0.04 0.1
Balloon cell melanoma 3 0.03 0.06
Mucosal lentiginous melanoma 3 0.03 0.06
NOS = not otherwise specified.
Fig. 2. Distribution of melanoma incidence as a frequency count (and as a percentage of all body sites in 
parentheses) by anatomical site for the black African population group. (NOS = not otherwise specified.)
Cutaneous, lip: n=6 (0.5%)
Cutaneous, eyelid: n=5 (0.4%)
External ear: n=4 (0.3%)
Other areas of face: n=38 (3%)
n=80 (6%)
Scalp and neck: n=27 (2%)
Upper limb and shoulder: n=137 (11%)
Trunk:
n=146 (11%)
Lower limb and hip: n= 921 (71%)
Cutaneous, genitalia: n=7 (0.5%)
• Skin, NOS: n=545 (30% of total group of 
cutaneous melanomas) 
This group was excluded from this diagram, 
which shows relative frequencies of involvement 
among 1 291 cutaneous melanomas in 
black Africans with known location
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individual and family history of melanoma[22] and unique geographi-
cal features. [23] No in-depth analysis exists comparing melanoma 
risk profiles of South Africans and Australians. Australia’s popula-
tion comprises about 90% white citizens by informal estimates,[24] 
although it is impossible to quote an exact percentage as Australia’s 
census does not collect ethnicity data in this way.[25]
With regard to other population groups, the reason for the slight 
decline in the incidence among black Africans compared with 
earlier studies is unclear. Missed cases may be the cause. Changes 
have also occurred in the demography of black Africans, where 
international immigrants comprise 4.2% of the population and 75.5% 
of immigrants come from other African countries.[26] Although the 
NCR makes every effort to only include SA residents’ data, some non-
SA citizens may be included.
Differences in melanoma incidence by province in which diagnoses 
were made may be influenced by the population group ratios, which 
differ by province. Gauteng and the Western Cape were home to 
1 913 886 and 915 055 white citizens, respectively, of a total of 
4 586 838 white South Africans at the 2011 census.[27] These provinces 
are probably important sites for patient and professional melanoma 
education, but patients may also have travelled from other provinces 
to seek dermatology services in large cities, so nationwide melanoma 
education is still important.
While the Western Cape is far south,[28] there are other potentially 
confounding factors (e.g. lifestyle choices such as tanning) that may 
be responsible for the higher incidence observed in Cape Town 
compared with Johannesburg, in Gauteng. No association was 
observed in melanoma incidence variation from province to province 
by latitude, but provincial population group proportions and other 
confounders were not taken into account.
Nearly 75% of all melanoma cases originated in the private sector. 
These were all invasive melanomas and therefore unlikely to be due to 
‘over-representation’ of early diagnoses. This discrepancy is probably 
related to divisions of healthcare (private v. public) by population 
group. A sizeable proportion (75%) of black African patients with 
melanoma were diagnosed in the state sector (probably because fewer 
black Africans than whites have medical insurance),[29] demonstrating 
that teaching about melanoma is important for healthcare providers 
in both sectors.
With regard to anatomical distribution of melanoma, lesions of the 
lower limb and hip were most common, followed by truncal lesions, 
then upper limb and shoulder lesions and finally those of head and 
neck. Typically truncal lesions were most common in white males, 
who generally had the highest incidence.[3,30] This is probably due 
to the relatively large population of black Africans in SA frequently 
developing melanoma on the limbs, particularly the lower limbs, and 
the fact that melanomas of the leg are typically reported to be more 
common in white females (we did not examine this specifically).[8]
A unique aspect of this study was the detailed analysis of reports 
specifically for black Africans. Where morphology was known, acral 
lentiginous melanoma predominated, which was not surprising 
as other studies have also found this the most common type of 
melanoma among deeply pigmented individuals.[31,32] Representation 
of other histological subtypes suggests that not all hand and foot 
melanomas conform to the acral lentiginous histological subtype.[11]
The male/female ratio among black Africans with limb melanoma 
showed a significant female preponderance. Previous studies of acral 
melanoma have observed a female preponderance in both South 
African[33] and other population groups.[32] Similar to all population 
groups, black Africans tended to be ≥60 years old, as reported in 
other SA studies.[34,35]
A predominance of lesions of the lower limb and foot was 
identified in black Africans. The hand/foot ratio of close to 1:13 was 
similar to a previous systematic review reporting a hand/foot ratio of 
between 1:13 and 1:3 - 1:4.[11] While there is a strong perception that 
melanoma does not occur in deeply pigmented individuals, our study 
showed that ~17% of melanomas occurred in black Africans. Just 
over 80% of these patients had limb melanomas, which would include 
(but are not exclusive to) melanoma of the palms, soles and nail beds. 
A large proportion of cases were coded as ‘Skin, NOS’; however, 146 
were reported on the trunk and 80 on the head and neck, refuting 
the notion that black African patients do not develop melanomas 
at these sites. With regard to mucosal melanomas, 33 of 67 of these 
lesions occurred in black Africans, slightly higher than expected as 
the incidence of mucosal melanoma in white individuals has been 
reported as being twice that in black individuals.[36]
It is recognised that melanoma behaves differently, is less common 
and has a poorer prognosis (often with late-stage presentation) 
in deeply pigmented individuals.[10,13] BD is considered the single 
most important prognostic factor for melanoma,[3] yet only 39% of 
pathology reports analysed in the present study contained a BD. 
Where BD was available it was >4 mm in most cases, conferring a 
Table 6. Relative frequencies of pathological (morphological) subtypes of melanoma reported in the black African population 




% after exclusion of NOS 
code (N=493)
Malignant melanoma, NOS (except juvenile melanoma) 385 44 -
Acral lentiginous melanoma 321 37 65
Nodular melanoma 48 5 10
Epithelioid cell melanoma 39 4 8
Spindle cell melanoma, NOS 24 3 5
Mixed epithelioid and spindle cell melanoma 20 2 4
Superficial spreading melanoma 15 2 3
Amelanotic melanoma 13 1 3
Desmoplastic melanoma 4 0.4 0.8
Malignant melanoma in a giant pigmented naevus 4 0.4 0.8
Lentigo maligna melanoma 3 0.3 0.6
Blue naevus, malignant 1 0.1 0.2
Malignant melanoma in junctional naevus 1 0.1 0.2
NOS = not otherwise specified.
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poor prognosis. The deepest BD of 95 mm was striking, suggesting a 
large, neglected tumour. Presentation with large BDs is an indicator 
of missed opportunities where patients should have been diagnosed 
earlier. While not possible with our data, it would have been 
interesting to perform an inter-population group comparison of BD 
to find out whether or not white patients were diagnosed earlier. One 
would expect them to be, since medical practitioners are anecdotally 
considered to be aware of the danger of melanoma in whites, and 
there are inherent challenges in diagnosing melanoma in darker skin 
types.[10] A recent study documenting a cohort of 66 SA patients with 
acral melanoma demonstrated higher BDs in black patients than in 
other population groups.[33]
Staging data were extremely limited, and it was difficult to make 
robust conclusions. There is probably also a bias towards reporting of 
late staging, as this is often only definitive with pathology specimen 
submission when metastatic disease is apparent.
Study limitations
Our study was novel in reporting detailed information on BD and 
stage at diagnosis among black South Africans; however, several 
limitations were noted. Within the scope of the study, a manual 
exercise to search original records was done specifically for cases of 
melanoma of the limbs in black Africans in the public sector, but not 
for any other groups or melanoma types owing to the scale of this 
task. Melanoma of the limbs in black Africans was chosen because 
it has been reported as the most common melanoma type in deeply 
pigmented patients and is associated with a poor prognosis.[10,34]
It must be noted that under-reporting to the NCR is still likely, and 
there is no control in place to confirm accuracy. Future monitoring 
and analysis are mandatory to validate these outcomes. It cannot be 
assumed that these numbers reflect accurate incidence rates – they 
merely provide an early estimate that needs to be followed up and 
validated. There may still be melanoma cases that were missed 
(e.g. where diagnoses were not confirmed with pathology). Despite 
success of mandatory cancer reporting, pathology-based registries 
have innate limitations. Cancers diagnosed based on clinical 
examination alone or radiology (without histology), for example, 
will not be included. However, it would be unusual for melanoma 
to be diagnosed in this way. The effect of reduced reporting prior to 
2011 is an important bias that we tried to overcome by reporting the 
incidence for post-2011. Time must be allowed for data collection by 
the NCR to stabilise.
Another limitation when reporting numbers of patients referred 
by private and public laboratories is that laboratories in academic 
centres may receive specimens as referrals from private laboratories 
when there are difficulties with diagnosis. Similarly, interprovincial 
referral of specimens may occur, but systems are in place to exclude 
duplications as well as to handle incomplete information.
While the NCR does not collect data on in situ lesions, this is in 
line with the approach of other registries.[14] A limitation is exclusion 
of very poorly differentiated tumours that could not be categorised 
as melanoma. The ICD-O topographical divisions were too broad 
to completely satisfy an investigation of acral melanoma in black 
African patients.
The frequency of NOS codes, while a relief for time-strapped 
healthcare workers, results in a blind spot. Pathology reporting on 
melanomas should be more detailed and standardised; for example, 
reporting on precise location, BD, presence/absence of metastatic 
disease and comorbidities would be optimal. Follow-up data on 
disease progression and survival are essential to provide a more 
complete picture of the impact of melanoma. Future analyses may 
show that increases in incidence are due to an increase in diagnosis of 
thinner melanoma, as observed elsewhere,[6] an indicator of success of 
education programmes provided by the Cancer Association of South 
Africa, medical professionals and other healthcare providers.
Conclusions
This study has provided a basis for obtaining more accurate 
melanoma incidence data and monitoring changes in incidence 
rates. It highlights melanoma in black Africans, emphasising that 
it is a significant public health problem, particularly because of 
late diagnosis. The findings are important to increase physician 
awareness and to strengthen public health education for melanoma 
primary and secondary prevention in SA.
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